Clinical Trial Update: Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Lutetium-177 DOTA-EB-FAPI in patients with metastatic, radioiodine-refractory thyroid cancer has completed enrollment, includi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Thyroid Carcinoma
• Hurthle Cell Carcinoma of the Thyroid
• Papillary Thyroid Carcinoma
• Radioiodine-refractory Thyroid Cancer

Drugs mentioned

• 177Lu-DOTA-EB-FAPI (Lutetium-177 DOTA-EB-FAPI)

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma | Phase 1 | Status: COMPLETED